Skin Cancer Therapeutics Market 2027 By isease Type, Treatment, End User and Geography | The Insight Partners

Skin Cancer Therapeutics Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By isease Type (Melanoma, Non-melanoma); Treatment (Chemotherapy, Radiotherapy, Cryosurgery, Immunotherapy, Photodynamic Therapy, Surgery, Other Treatments); End User (Hospital And Clinics, Diagnostic Centres, Cancer Research Institute, Others) and Geography

Report Code: TIPRE00004754 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
Covid
MARKET INTRODUCTION
Skin cancer is caused due to uncontrolled division of skin cells, which often develops when the skin exposed to the sun. In this condition, the cells stop responding to the body signals and also lead the skin cells to multiply rapidly and form malignant tumors. There are three major types of skin cancer namely, melanoma, basal cell carcinoma, and squamous cell carcinoma. Various therapeutic treatments are available for skin cancer, which depends on the location and size of the tumor, the microscopic characteristics of cancer, and the general health of the patient.

MARKET DYNAMICS
The skin cancer therapeutics market is anticipated to grow in the forecast period owing to increase in number of cancer patients, increasing R&D activities and growing awareness about cancer across the globe. However, the rising demand for the innovative and effective therapies in the treatment of monoclonal antibodies is likely to grow the market during the forecast period.

MARKET SCOPE
The "Global Skin Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of skin cancer therapeutics market with detailed market segmentation by disease type, treatment, end user and geography. The global skin cancer therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading enteral feeding formulas market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global skin cancer therapeutics market is segmented on the basis of disease type, treatment and end user. Based on disease type, the market is bifurcated into melanoma and non-melanoma. On the basis of treatment, the market is classified as chemotherapy, radiotherapy, cryosurgery, immunotherapy, photodynamic therapy, surgery and other treatments. Based on end user the skin cancer therapeutics market is divided as hospital and clinics, diagnostic centers, cancer research institute and others.

Get more information on this report :

REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global skin cancer therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The skin cancer therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting skin cancer therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the skin cancer therapeutics market in these regions.

Get more information on this report :

MARKET PLAYERS
The reports cover key developments in the skin cancer therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from skin cancer therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for skin cancer therapeutics market in the global market. Below mentioned is the list of few companies engaged in the skin cancer therapeutics market.

The report also includes the profiles of key skin cancer therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd
  • Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
  • Mylan N.V.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • Sensus Healthcare
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Skin Cancer Therapeutics Market - By Disease Type
1.3.2 Skin Cancer Therapeutics Market - By Treatment
1.3.3 Skin Cancer Therapeutics Market - By End User
1.3.4 Skin Cancer Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. SKIN CANCER THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. SKIN CANCER THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. SKIN CANCER THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. SKIN CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. SKIN CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. SKIN CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. MELANOMA
7.3.1. Overview
7.3.2. Melanoma Market Forecast and Analysis
7.4. NON-MELANOMA
7.4.1. Overview
7.4.2. Non-melanoma Market Forecast and Analysis
8. SKIN CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. CHEMOTHERAPY
8.3.1. Overview
8.3.2. Chemotherapy Market Forecast and Analysis
8.4. RADIOTHERAPY
8.4.1. Overview
8.4.2. Radiotherapy Market Forecast and Analysis
8.5. CRYOSURGERY
8.5.1. Overview
8.5.2. Cryosurgery Market Forecast and Analysis
8.6. IMMUNOTHERAPY
8.6.1. Overview
8.6.2. Immunotherapy Market Forecast and Analysis
8.7. PHOTODYNAMIC THERAPY
8.7.1. Overview
8.7.2. Photodynamic Therapy Market Forecast and Analysis
8.8. SURGERY
8.8.1. Overview
8.8.2. Surgery Market Forecast and Analysis
8.9. OTHER TREATMENTS
8.9.1. Overview
8.9.2. Other Treatments Market Forecast and Analysis
9. SKIN CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL AND CLINICS
9.3.1. Overview
9.3.2. Hospital And Clinics Market Forecast and Analysis
9.4. DIAGNOSTIC CENTRES
9.4.1. Overview
9.4.2. Diagnostic Centres Market Forecast and Analysis
9.5. CANCER RESEARCH INSTITUTE
9.5.1. Overview
9.5.2. Cancer Research Institute Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. SKIN CANCER THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Skin Cancer Therapeutics Market Overview
10.1.2 North America Skin Cancer Therapeutics Market Forecasts and Analysis
10.1.3 North America Skin Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
10.1.4 North America Skin Cancer Therapeutics Market Forecasts and Analysis - By Treatment
10.1.5 North America Skin Cancer Therapeutics Market Forecasts and Analysis - By End User
10.1.6 North America Skin Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Skin Cancer Therapeutics Market
10.1.6.1.1 United States Skin Cancer Therapeutics Market by Disease Type
10.1.6.1.2 United States Skin Cancer Therapeutics Market by Treatment
10.1.6.1.3 United States Skin Cancer Therapeutics Market by End User
10.1.6.2 Canada Skin Cancer Therapeutics Market
10.1.6.2.1 Canada Skin Cancer Therapeutics Market by Disease Type
10.1.6.2.2 Canada Skin Cancer Therapeutics Market by Treatment
10.1.6.2.3 Canada Skin Cancer Therapeutics Market by End User
10.1.6.3 Mexico Skin Cancer Therapeutics Market
10.1.6.3.1 Mexico Skin Cancer Therapeutics Market by Disease Type
10.1.6.3.2 Mexico Skin Cancer Therapeutics Market by Treatment
10.1.6.3.3 Mexico Skin Cancer Therapeutics Market by End User
10.2. EUROPE
10.2.1 Europe Skin Cancer Therapeutics Market Overview
10.2.2 Europe Skin Cancer Therapeutics Market Forecasts and Analysis
10.2.3 Europe Skin Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
10.2.4 Europe Skin Cancer Therapeutics Market Forecasts and Analysis - By Treatment
10.2.5 Europe Skin Cancer Therapeutics Market Forecasts and Analysis - By End User
10.2.6 Europe Skin Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Skin Cancer Therapeutics Market
10.2.6.1.1 Germany Skin Cancer Therapeutics Market by Disease Type
10.2.6.1.2 Germany Skin Cancer Therapeutics Market by Treatment
10.2.6.1.3 Germany Skin Cancer Therapeutics Market by End User
10.2.6.2 France Skin Cancer Therapeutics Market
10.2.6.2.1 France Skin Cancer Therapeutics Market by Disease Type
10.2.6.2.2 France Skin Cancer Therapeutics Market by Treatment
10.2.6.2.3 France Skin Cancer Therapeutics Market by End User
10.2.6.3 Italy Skin Cancer Therapeutics Market
10.2.6.3.1 Italy Skin Cancer Therapeutics Market by Disease Type
10.2.6.3.2 Italy Skin Cancer Therapeutics Market by Treatment
10.2.6.3.3 Italy Skin Cancer Therapeutics Market by End User
10.2.6.4 Spain Skin Cancer Therapeutics Market
10.2.6.4.1 Spain Skin Cancer Therapeutics Market by Disease Type
10.2.6.4.2 Spain Skin Cancer Therapeutics Market by Treatment
10.2.6.4.3 Spain Skin Cancer Therapeutics Market by End User
10.2.6.5 United Kingdom Skin Cancer Therapeutics Market
10.2.6.5.1 United Kingdom Skin Cancer Therapeutics Market by Disease Type
10.2.6.5.2 United Kingdom Skin Cancer Therapeutics Market by Treatment
10.2.6.5.3 United Kingdom Skin Cancer Therapeutics Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Skin Cancer Therapeutics Market Overview
10.3.2 Asia-Pacific Skin Cancer Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Skin Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
10.3.4 Asia-Pacific Skin Cancer Therapeutics Market Forecasts and Analysis - By Treatment
10.3.5 Asia-Pacific Skin Cancer Therapeutics Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Skin Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Skin Cancer Therapeutics Market
10.3.6.1.1 Australia Skin Cancer Therapeutics Market by Disease Type
10.3.6.1.2 Australia Skin Cancer Therapeutics Market by Treatment
10.3.6.1.3 Australia Skin Cancer Therapeutics Market by End User
10.3.6.2 China Skin Cancer Therapeutics Market
10.3.6.2.1 China Skin Cancer Therapeutics Market by Disease Type
10.3.6.2.2 China Skin Cancer Therapeutics Market by Treatment
10.3.6.2.3 China Skin Cancer Therapeutics Market by End User
10.3.6.3 India Skin Cancer Therapeutics Market
10.3.6.3.1 India Skin Cancer Therapeutics Market by Disease Type
10.3.6.3.2 India Skin Cancer Therapeutics Market by Treatment
10.3.6.3.3 India Skin Cancer Therapeutics Market by End User
10.3.6.4 Japan Skin Cancer Therapeutics Market
10.3.6.4.1 Japan Skin Cancer Therapeutics Market by Disease Type
10.3.6.4.2 Japan Skin Cancer Therapeutics Market by Treatment
10.3.6.4.3 Japan Skin Cancer Therapeutics Market by End User
10.3.6.5 South Korea Skin Cancer Therapeutics Market
10.3.6.5.1 South Korea Skin Cancer Therapeutics Market by Disease Type
10.3.6.5.2 South Korea Skin Cancer Therapeutics Market by Treatment
10.3.6.5.3 South Korea Skin Cancer Therapeutics Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Skin Cancer Therapeutics Market Overview
10.4.2 Middle East and Africa Skin Cancer Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Skin Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
10.4.4 Middle East and Africa Skin Cancer Therapeutics Market Forecasts and Analysis - By Treatment
10.4.5 Middle East and Africa Skin Cancer Therapeutics Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Skin Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Skin Cancer Therapeutics Market
10.4.6.1.1 South Africa Skin Cancer Therapeutics Market by Disease Type
10.4.6.1.2 South Africa Skin Cancer Therapeutics Market by Treatment
10.4.6.1.3 South Africa Skin Cancer Therapeutics Market by End User
10.4.6.2 Saudi Arabia Skin Cancer Therapeutics Market
10.4.6.2.1 Saudi Arabia Skin Cancer Therapeutics Market by Disease Type
10.4.6.2.2 Saudi Arabia Skin Cancer Therapeutics Market by Treatment
10.4.6.2.3 Saudi Arabia Skin Cancer Therapeutics Market by End User
10.4.6.3 U.A.E Skin Cancer Therapeutics Market
10.4.6.3.1 U.A.E Skin Cancer Therapeutics Market by Disease Type
10.4.6.3.2 U.A.E Skin Cancer Therapeutics Market by Treatment
10.4.6.3.3 U.A.E Skin Cancer Therapeutics Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Skin Cancer Therapeutics Market Overview
10.5.2 South and Central America Skin Cancer Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Skin Cancer Therapeutics Market Forecasts and Analysis - By Disease Type
10.5.4 South and Central America Skin Cancer Therapeutics Market Forecasts and Analysis - By Treatment
10.5.5 South and Central America Skin Cancer Therapeutics Market Forecasts and Analysis - By End User
10.5.6 South and Central America Skin Cancer Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Skin Cancer Therapeutics Market
10.5.6.1.1 Brazil Skin Cancer Therapeutics Market by Disease Type
10.5.6.1.2 Brazil Skin Cancer Therapeutics Market by Treatment
10.5.6.1.3 Brazil Skin Cancer Therapeutics Market by End User
10.5.6.2 Argentina Skin Cancer Therapeutics Market
10.5.6.2.1 Argentina Skin Cancer Therapeutics Market by Disease Type
10.5.6.2.2 Argentina Skin Cancer Therapeutics Market by Treatment
10.5.6.2.3 Argentina Skin Cancer Therapeutics Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. SKIN CANCER THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. AMGEN INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BRISTOL-MYERS SQUIBB COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. DAIICHI SANKYO COMPANY, LIMITED
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. F. HOFFMANN-LA ROCHE LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK SHARP AND DOHME CORP.(MERCK AND CO., INC.)
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN N.V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SUN PHARMACEUTICAL INDUSTRIES LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. VARIAN MEDICAL SYSTEMS, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SENSUS HEALTHCARE
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Amgen Inc.
2. Bristol-Myers Squibb Company
3. DAIICHI SANKYO COMPANY, LIMITED
4. F. Hoffmann-La Roche Ltd
5. Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
6. Mylan N.V.
7. Novartis AG
8. Sun Pharmaceutical Industries Ltd.
9. Varian Medical Systems, Inc.
10. Sensus Healthcare
TIPRE00004754
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking